Kailera Therapeutics, Inc.’s (NASDAQ:KLRA) Lock-Up Period Set To End on October 14th

Kailera Therapeutics’ (NASDAQ:KLRA) lock-up period will expire on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its IPO on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Trading Up 16.1%

KLRA opened at $11.61 on Friday. The firm’s fifty day moving average is $15.03. Kailera Therapeutics has a 52-week low of $9.76 and a 52-week high of $28.23. The stock has a market capitalization of $1.51 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, sell-side analysts expect that Kailera Therapeutics will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $309,000. Mirador Capital Partners LP acquired a new stake in Kailera Therapeutics during the third quarter worth $666,000. Squarepoint Ops LLC purchased a new stake in Kailera Therapeutics in the 2nd quarter valued at about $993,000. State Street Corp purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $19,126,000. Finally, Frazier Life Sciences Management L.P. acquired a new position in Kailera Therapeutics during the second quarter worth $24,233,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.